Plague Pipeline

Emptied bacterial envelopes produced with a phage lytic system

The same Obolensk center that makes PMMM. Bacterial envelopes emptied with a phage lysis system, then stripped of peptidoglycan so the shells are less inflammatory. Reported in 2022. The briefing does not name the animal model. Preclinical, and the center is a state institute, not a stock.

Stage chart

Preclinical

Phase 1

Phase 2

Phase 3

Licensed

Preclinical. Phase 3 is empty here, as it is for every programme in the set.

Years on the record

A mark at 2022. Labelled “2022” on the briefing. Not a forecast.

Analyst card

Challenge: The briefing does not name the animal model or the form of plague.
F1-negative strains: Not reported.
Adjuvant: None named. Peptidoglycan was removed to cut inflammation.
Route: Not stated.
Stability: Formulation and cold-chain requirement are not stated.
Time to protection: Not reported. No time-to-protection figure is in the briefing.
Other threats: Plague only, as far as the briefing goes.
Survival figure: No survival figure. The model itself is not stated.
Animal Rule: Preclinical. Not an Animal Rule file.

Pipeline record

Lab: Obolensk, the same state center that makes PMMM.
Method: A phage lysis system empties the bacterium. Peptidoglycan is then removed so the shell is less inflammatory.
Year: 2022.
Gap: The briefing does not name the animal model. Preclinical. Not a stock.

News

Checking today’s headlines.

Latest intel

Checking Europe PMC.

PubMed

Checking today’s index.

Platform: Bacterial / OMV
Outer-membrane vesicles, or emptied bacterial envelopes called ghosts, used as a package for antigens rather than as an infection.
Who is paying: Russia — State Res. Ctr. for Applied Microbiology
Country: Russia
What was tested: Not stated
Stage: Preclinical
Date: 2022